{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:36:50Z","timestamp":1778776610849,"version":"3.51.4"},"reference-count":24,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":583,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1111\/ijcp.12343","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T03:36:17Z","timestamp":1390793777000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Indirect treatment comparison between fixed-dose-combinations of amlodipine\/losartan and amlodipine\/valsartan in blood pressure control"],"prefix":"10.1155","volume":"68","author":[{"given":"A.","family":"Lawrence Gould","sequence":"first","affiliation":[{"name":"Merck Research Laboratories; West Point PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Unniachan","sequence":"additional","affiliation":[{"name":"Global Health Outcomes; Merck & Co., Inc.; Whitehouse Station NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wu","sequence":"additional","affiliation":[{"name":"Global Health Outcomes; Merck & Co., Inc.; Whitehouse Station NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2014,1,26]]},"reference":[{"key":"10.1111\/ijcp.12343-BIB0001|ijcp12343-cit-0001","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","article-title":"Global burden of blood-pressure-related disease, 2001","volume":"371","author":"Lawes","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12343-BIB0002|ijcp12343-cit-0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/HJH.0b013e328010775f","article-title":"Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region","volume":"25","author":"Martiniuk","year":"2007","journal-title":"J Hypertens"},{"key":"10.1111\/ijcp.12343-BIB0003|ijcp12343-cit-0003","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/HJH.0b013e3283282f65","article-title":"Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries","volume":"27","author":"Pereira","year":"2009","journal-title":"J Hypertens"},{"key":"10.1111\/ijcp.12343-BIB0004|ijcp12343-cit-0004","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/ijcp.12343-BIB0005|ijcp12343-cit-0005","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension","volume":"21","author":"Whitworth","year":"2003","journal-title":"J Hypertens"},{"key":"10.1111\/ijcp.12343-BIB0006|ijcp12343-cit-0006","first-page":"1462","article-title":"2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12343-BIB0007|ijcp12343-cit-0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1111\/ijcp.12343-BIB0008|ijcp12343-cit-0008","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"10.1111\/ijcp.12343-BIB0009|ijcp12343-cit-0009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1111\/ijcp.12343-BIB0010|ijcp12343-cit-0010","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007995.2010.534129","article-title":"Adherence and persistence of single-pill ARB\/CCB combination therapy compared to multiple-pill ARB\/CCB regimens","volume":"26","author":"Zeng","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12343-BIB0011|ijcp12343-cit-0011","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2011.596873","article-title":"Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan\/amlodipine single-pill combination versus angiotensin receptor blocker\/calcium channel blocker free-combination therapy","volume":"14","author":"Baser","year":"2011","journal-title":"J Med Econ"},{"key":"10.1111\/ijcp.12343-BIB0012|ijcp12343-cit-0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/VHRM.S3134","article-title":"Amlodipine and valsartan as components of a rational and effective fixed-dose combination","volume":"5","author":"Waeber","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1111\/ijcp.12343-BIB0013|ijcp12343-cit-0013","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/VHRM.S2586","article-title":"Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination","volume":"4","author":"Pimenta","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1111\/ijcp.12343-BIB0014|ijcp12343-cit-0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11597410-000000000-00000","article-title":"Comparison of the efficacy and safety of fixed-dose amlodipine\/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study","volume":"12","author":"Hong","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1111\/ijcp.12343-BIB0015|ijcp12343-cit-0015","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.clinthera.2011.11.007","article-title":"Comparative efficacy and safety profile of amlodipine 5\u00a0mg\/losartan 50\u00a0mg fixed-dose combination and amlodipine 10\u00a0mg monotherapy in hypertensive patients who respond poorly to amlodipine 5\u00a0mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study","volume":"33","author":"Kang","year":"2011","journal-title":"Clin Ther"},{"key":"10.1111\/ijcp.12343-BIB0016|ijcp12343-cit-0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11597170-000000000-00000","article-title":"Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study","volume":"12","author":"Park","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1111\/ijcp.12343-BIB0017|ijcp12343-cit-0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1111\/ijcp.12343-BIB0018|ijcp12343-cit-0018","unstructured":"European Medicines Agency European public assessment report (EPAR) Exforge 2009"},{"issue":"264-9","key":"10.1111\/ijcp.12343-BIB0019|ijcp12343-cit-0019","first-page":"W64","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12343-BIB0020|ijcp12343-cit-0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/ijcp.12343-BIB0021|ijcp12343-cit-0021","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","article-title":"Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension","volume":"29","author":"Philipp","year":"2007","journal-title":"Clin Ther"},{"key":"10.1111\/ijcp.12343-BIB0022|ijcp12343-cit-0022","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1185\/03007995.2010.487391","article-title":"Efficacy and safety of a single-pill combination of amlodipine\/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy","volume":"26","author":"Ke","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12343-BIB0023|ijcp12343-cit-0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1742-1241.2008.01977.x","article-title":"The combination of amlodipine\/valsartan 5\/160\u00a0mg produces less peripheral oedema than amlodipine 10\u00a0mg in hypertensive patients not adequately controlled with amlodipine 5\u00a0mg","volume":"63","author":"Schrader","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12343-BIB0024|ijcp12343-cit-0024","first-page":"CD003823","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","volume":"4","author":"Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:07:59Z","timestamp":1643350079000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,26]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12343","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,26]]},"assertion":[{"value":"2014-01-26","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}